Abstract
Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.
| Original language | English |
|---|---|
| Pages (from-to) | 798-801 |
| Number of pages | 4 |
| Journal | Blood |
| Volume | 134 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Sep 5 2019 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
Early progression as a predictor of survival in marginal zone lymphomas : an analysis from the FIL-NF10 study. / Luminari, Stefano; Merli, Michele; Rattotti, Sara; Tarantino, Vittoria; Marcheselli, Luigi; Cavallo, Federica; Varettoni, Marzia; Bianchi, Benedetta; Merli, Francesco; Tedeschi, Alessandra; Cabras, Giuseppina; Re, Francesca; Visco, Carlo; Torresan Delamain, Marcia; Cencini, Emanuele; Spina, Michele; Ferrero, Simone; Ferrari, Angela; Deodato, Marina; Mannina, Donato; Annibali, Ombretta; Rago, Angela; Orsucci, Lorella; Defrancesco, Irene; Frigeni, Marco; Cesaretti, Marina; Arcaini, Luca.
In: Blood, Vol. 134, No. 10, 05.09.2019, p. 798-801.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early progression as a predictor of survival in marginal zone lymphomas
T2 - an analysis from the FIL-NF10 study
AU - Luminari, Stefano
AU - Merli, Michele
AU - Rattotti, Sara
AU - Tarantino, Vittoria
AU - Marcheselli, Luigi
AU - Cavallo, Federica
AU - Varettoni, Marzia
AU - Bianchi, Benedetta
AU - Merli, Francesco
AU - Tedeschi, Alessandra
AU - Cabras, Giuseppina
AU - Re, Francesca
AU - Visco, Carlo
AU - Torresan Delamain, Marcia
AU - Cencini, Emanuele
AU - Spina, Michele
AU - Ferrero, Simone
AU - Ferrari, Angela
AU - Deodato, Marina
AU - Mannina, Donato
AU - Annibali, Ombretta
AU - Rago, Angela
AU - Orsucci, Lorella
AU - Defrancesco, Irene
AU - Frigeni, Marco
AU - Cesaretti, Marina
AU - Arcaini, Luca
PY - 2019/9/5
Y1 - 2019/9/5
N2 - Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.
AB - Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.
UR - http://www.scopus.com/inward/record.url?scp=85071786735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071786735&partnerID=8YFLogxK
U2 - 10.1182/blood.2019001088
DO - 10.1182/blood.2019001088
M3 - Article
C2 - 31292118
AN - SCOPUS:85071786735
VL - 134
SP - 798
EP - 801
JO - Blood
JF - Blood
SN - 0006-4971
IS - 10
ER -